Efficacy of imiquimod, an immunomodulatory agent, on experimental endometriosis

Devrim Altintas, Altintas D, Kokcu A, Arif Kokcu, Arif Kökçü, Kandemir B, Bedri Kandemir, Bedrı Kandemır, Cetinkaya MB, Mehmet B Cetinkaya, Mehmet Çetinkaya, Migraci Tosun, Miğraci Tosun, Tosun M
Fertility and sterility · 2007 · vol. 90(2) , pp. 401–405 · doi:10.1016/j.fertnstert.2007.06.057 · PMID:17980874 · W2087839838
article OA: closed CC0 ⤵ 14 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This study investigated the efficacy of the immunomodulatory agent imiquimod in an experimental model of endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo investigate the efficacy of imiquimod on endometriosis.DesignRandomized, placebo-controlled, single-blind, experimental study.SettingExperimental surgery laboratory at a university in Turkey.Animal(s)Thirty Wistar female rats.Intervention(s)After the peritoneal implantation of endometrial tissue, rats were randomized to two equal intervention groups: [1] the control group and [2] the imiquimod group. Six weeks later, after implant volume was measured (volume 1) by performing a second laparotomy, imiquimod (10 mg intraperitoneally per rat, 2 times per wk) was administered to the imiquimod group, and saline solution (0.1 mL SC, once per wk), to the control group, for 8 weeks. At the end of the treatment, a third laparotomy was performed to remeasure implant volumes (volume 2), and implants were totally excised for histopathologic examination.Main outcome measure(s)To compare volume 1 and volume 2 within the groups, as well as stromal and glandular tissues between the groups.Result(s)In the imiquimod group, volume 2 was statistically significantly reduced compared with volume 1, whereas there was no significant volume change in the control group. In the imiquimod group, when compared with the control group, both glandular and stromal tissues had statistically significantly lessened.Conclusion(s)Imiquimod was seen to regress significantly both the size and the histological structure of endometriotic implants.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Adjuvants, Immunologic Aminoquinolines Endometriosis Adjuvants, Immunologic Aminoquinolines Animals Disease Models, Animal Endometriosis Endometriosis Endometrium Endometrium Endometrium Female Imiquimod Random Allocation Rats Rats, Wistar

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (40)

Cited by (15)

Source provenance

europepmc
last seen: 2026-08-15T06:15:18.721777+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:14:48.452140+00:00
License: CC0 · commercial use OK